Logo Logo Logo Logo Logo
  • COMPANY
    • ABOUT US
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Business Development
    • Main Investors
    • CONTACT US
  • SCIENCE
    • SNP-Technology
    • Intellectual Property
  • PIPELINE
    • Overview
    • OCS-01 Diabetic macular edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Uveitis
    • OCS-02 Dry Eye
  • NEWS
    • Press releases
  • CAREERS
  • COMPANY

    • ABOUT US
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Business Development
    • Main Investors
    • CONTACT US
  • SCIENCE

    • SNP-Technology
    • Intellectual Property
  • PIPELINE

    • Overview
    • OCS-01 Diabetic macular edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Uveitis
    • OCS-02 Dry Eye
  • NEWS

    • Press releases
  • CAREERS
Oculis Appoints Dr. Frédéric Pilotaz as VP of Technology & Pharmaceutical Sciences

...

21 April, 2020
Oculis Appoints Marcia de Souza Lima, M.D., as Chief Medical Officer
03 March, 2020
Phase 2 Study Results of OCS-01: A Potential Topical Therapeutic for DME
10 February, 2020
Oculis Announces Upcoming Presentation of Phase 2 Data of OCS-01 in DME
22 January, 2020
Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Trial
07 October, 2019
Oculis Announces Appointment of Leading Specialists to Scientific Advisory Board
17 September, 2019
Why a pharma investor quit his day job to follow a vision (Guest interview)
16 May, 2019
Oculis Expands Portfolio with a Novel Phase II-stage Anti-TNF alpha Antibody Fragment
04 January, 2019
Oculis Raises CHF15.5 million in an Extension of its Series B Financing Round
04 January, 2019
Oculis Strengthens its Global Clinical and Business Development Capabilities
20 November, 2018
Show more
Contact us

Oculis Switzerland
Corporate Headquarters
EPFL Innovation Park Building D
Route J-D. Colladon
1015 Lausanne
Switzerland

+41 21 711 3970

 

Oculis Iceland
Alfheimar 74
6th Floor
104 Reykjavik
Iceland

+354 546 4440

Copyright © 2020 Oculis SA.

    © Oculis – Private policy

    © L’autreagence 2019